Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 8:7:225.
doi: 10.3389/fmed.2020.00225. eCollection 2020.

Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context

Pascal Mertens  1 , Nathalie De Vos  2 , Delphine Martiny  3 , Christian Jassoy  4 , Ali Mirazimi  5 , Lize Cuypers  6   7 , Sigi Van den Wijngaert  3 , Vanessa Monteil  5 , Pierrette Melin  8 , Karolien Stoffels  3 , Nicolas Yin  3 , Davide Mileto  9 , Sabrina Delaunoy  3 , Henri Magein  1 , Katrien Lagrou  6   7 , Justine Bouzet  1 , Gabriela Serrano  3   10 , Magali Wautier  3 , Thierry Leclipteux  1 , Marc Van Ranst  6   7 , Olivier Vandenberg  10   11 ; LHUB-ULB SARS-CoV-2 Working Diagnostic Group
Collaborators, Affiliations

Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context

Pascal Mertens et al. Front Med (Lausanne). .

Abstract

Introduction: COVID-19 Ag Respi-Strip, an immunochromatographic (ICT) assay for the rapid detection of SARS-CoV-2 antigen on nasopharyngeal specimen, has been developed to identify positive COVID-19 patients allowing prompt clinical and quarantine decisions. In this original research article, we describe the conception, the analytical and clinical performances as well as the risk management of implementing the COVID-19 Ag Respi-Strip in a diagnostic decision algorithm. Materials and Methods: Development of the COVID-19 Ag Respi-Strip resulted in a ready-to-use ICT assay based on a membrane technology with colloidal gold nanoparticles using monoclonal antibodies directed against the SARS-CoV and SARS-CoV-2 highly conserved nucleoprotein antigen. Four hundred observations were recorded for the analytical performance study and thirty tests were analyzed for the cross-reactivity study. The clinical performance study was performed in a retrospective multi-centric evaluation on aliquots of 328 nasopharyngeal samples. COVID-19 Ag Respi-Strip results were compared with qRT-PCR as golden standard for COVID-19 diagnostics. Results: In the analytical performance study, the reproducibility showed a between-observer disagreement of 1.7%, a robustness of 98%, an overall satisfying user friendliness and no cross-reactivity with other virus-infected nasopharyngeal samples. In the clinical performance study performed in three different clinical laboratories during the ascendant phase of the epidemiological curve, we found an overall sensitivity and specificity of 57.6 and 99.5%, respectively with an accuracy of 82.6%. The cut-off of the ICT was found at CT <22. User-friendliness analysis and risk management assessment through Ishikawa diagram demonstrate that COVID-19 Ag Respi-Strip may be implemented in clinical laboratories according to biosafety recommendations. Conclusion: The COVID-19 Ag Respi-Strip represents a promising rapid SARS-CoV-2 antigen assay for the first-line diagnosis of COVID-19 in 15 min at the peak of the pandemic. Its role in the proposed diagnostic algorithm is complementary to the currently-used molecular techniques.

Keywords: COVID-19; SARS-CoV-2; antigen; diagnostic; immunochromatographic test.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Standard operating procedure SARS-CoV-2 Respi-Strip® from Coris BioConcept.
Figure 2
Figure 2
Proposal for a diagnostic decision algorithm.
Figure 3
Figure 3
Ishikawa diagram of rapid SARS-CoV-2 diagnostic tests for Clinical Labs' implementation. BSL-2, Biosafety Level 2; FAMHP, Belgian Federal Agency for Medicines and Health Products; FFP2, Filtering Facepiece Respirator Class 2; FPS Health, Belgian Federal Public Service Health, Food Chain Safety and Environment; IVDR, European Regulation 2017/746 on in vitro Diagnostic Medical Devices.
See this image and copyright information in PMC

Comment in

References

    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. . A novel Coronavirus from patients with Pneumonia in China, 2019. N Engl J Med. (2020) 382:727–33. 10.1056/NEJMoa2001017 - DOI - PMC - PubMed
    1. Rubin EJ, Baden LR, Morrissey S. Audio interview: new research on possible treatments for Covid-19. N Engl J Med. (2020) 382:e30. 10.1056/NEJMe2005759 - DOI - PubMed
    1. Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol. (2020) 1:9 10.1007/s00330-020-06801-0 - DOI - PMC - PubMed
    1. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. . COVID-19 infection: the perspectives on immune responses. Cell Death Differ. (2020) 27:1451–54. 10.1038/s41418-020-0530-3 - DOI - PMC - PubMed
    1. Che XY, Qiu LW, Pan YX, Wen K, Hao W, Zhang LY, et al. . Sensitive and specific monoclonal antibody-based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome. J Clin Microbiol. (2004) 42:2629–35. 10.1128/JCM.42.6.2629-2635.2004 - DOI - PMC - PubMed